Myeloid Leukemia

62 Picard, Silvy, and Gabert
Fig. 11. Longitudinal minimal residual disease (MRD) monitoring of an AML1-
ETO-positive patient using EAC AML1-ETO and ABL real-time quantitative polymerase
chain reaction sets. For each sample, the MRD value is a normalized copy
number (AML1-ETO copy number/ABL copy number) expressed as a percentage of
the Europe Against Cancer (EAC) median for the fusion gene transcript. The gray area
defines the EAC 95% range values for AML1-ETO normalized copy number (NCN).
The sensitivity is calculated according to the relative expression of the fusion gene
(FG) at diagnosis and control gene (CG) expression during follow-up. (1), EAC median
value for AML1-ETO NCN is set to 100%; (2), patient diagnostic sample; (3), example
of negative sample (i.e., “good quality sample” and absence of FG detection); (4),
example of “not quantifiable positive” sample—the sensitivity is correct, indicating
that ABL CN is >1000; therefore, the FG CN is